-Reuters
Amylyx Pharmaceuticals Q3 EPS $(0.92) Beats $(0.97) Estimate, Sales $345.00K Beat $80.00K Estimate
Amylyx Pharmaceuticals (NASDAQ:AMLX) reported quarterly losses of $(0.92) per share which beat the analyst consensus estimate of $(0.97) by 5.15 percent. The company reported quarterly sales of $345.00 thousand which